Quick Answer
Weight loss medications are typically used on an ongoing basis. NICE guidance notes that weight regain commonly occurs after stopping treatment. Your prescriber will discuss the appropriate duration based on your circumstances.
Detailed Answer
Weight loss medications such as Mounjaro, Wegovy, and Saxenda are generally intended for long-term use. NICE guidance explicitly notes that weight regain commonly occurs after stopping treatment, which is consistent with the clinical trial evidence.
The STEP 1 extension trial for semaglutide (Wegovy) showed that participants who discontinued the medication after 68 weeks regained approximately two-thirds of their weight loss within the following year. Similar patterns have been observed with other GLP-1 medications.
This does not mean that everyone must take medication indefinitely. Your prescriber will assess your progress regularly and discuss the appropriate duration based on factors including your weight loss response, health improvements, side effect profile, and personal preferences.
Under NICE guidance for tirzepatide (TA1026), treatment should be discontinued if a patient has not achieved at least 5% weight loss after six months at the maximum tolerated dose. This ensures that medication continues only when it is providing meaningful clinical benefit.
If you and your prescriber decide to stop medication, they will typically recommend a gradual discontinuation and emphasise the importance of maintaining the dietary and lifestyle changes you made during treatment. Some patients may require ongoing medication to maintain their weight loss, while others may manage with lifestyle strategies alone.